Abstract
We investigated an atypical form of limb-girdle muscular dystrophy type R3 (LGMDR3) associated with a homozygous synonymous variant in SGCA that significantly expands the recognized clinical phenotype to include prominent cardiac involvement. While LGMDR3, caused by pathogenic variants in SGCA, typically presents as progressive muscle weakness with relatively limited cardiac manifestations, the individuals in our study developed substantial left ventricular dysfunction, arrhythmias, and even life-threatening ventricular tachyarrhythmias.
Five consanguineous families, initially evaluated through exome sequencing, showed no conclusive results until a focused genotype-phenotype correlation reanalysis pinpointed a single homozygous synonymous SGCA variant. Despite its location distant from canonical splice sites, this variant disrupted normal mRNA splicing, leading to aberrant transcripts and, presumably, a nonfunctional or structurally altered α-sarcoglycan protein. Cardiac assessments, including echocardiography, Holter monitoring, and cardiac magnetic resonance imaging, revealed a spectrum of findings from mild asymptomatic dysfunction to severe dilated cardiomyopathy and malignant arrhythmias requiring implantable cardioverter-defibrillators.
This case broadens current understanding of LGMDR3 and its molecular underpinnings, ultimately guiding more personalized management strategies for affected individuals. It illustrates that thorough and ongoing variant interpretation is crucial, particularly in consanguineous populations where seemingly benign alterations may confer significant phenotypic consequences. By integrating carefully curated genomic data with clinical insights, clinicians can better identify patients at risk, tailor surveillance protocols, and implement timely interventions. In doing so, this discovery not only refines our appreciation of the intricate interplay between genetic variants and their phenotypic manifestations, but also underscores the importance of precision medicine approaches in the evolving landscape of inherited cardiomyopathies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee/IRB of Hadassah Hebrew University Medical Center (approval number 0151-20-HMO) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Non-standard Abbreviations and Acronyms
- CPK
- Creatine Phosphokinase
- CMR
- Cardiac Magnetic Resonance
- DAPC
- Dystrophin-Associated Protein Complex
- ECG
- Electrocardiogram
- ESE
- Exonic Splicing Enhancer
- ILR
- Internal Loop Recorder
- LGE
- Late Gadolinium Enhancement
- LGMDR3
- Limb-Girdle Muscular Dystrophy Type R3
- LV
- Left Ventricular
- LVEF
- Left Ventricular Ejection Fraction
- NDLVC
- Non-Dilated Left Ventricular Cardiomyopathy
- NIDCM
- Non-Ischemic Dilated Cardiomyopathy
- NSVT
- Non-Sustained Ventricular Tachycardia
- PMVT
- Polymorphic Ventricular Tachycardia
- PVCs
- Premature Ventricular Contractions
- ROH
- Region of Homozygosity
- RV
- Right Ventricular
- SCD
- Sudden Cardiac Death
- SGCA
- α-sarcoglycan
- VF
- Ventricular Fibrillation





